Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring Rheumatoid arthritis
Eligibility Criteria
Inclusion Criteria: Participation and completion until Week 24 of the prior adalimumab dose-ranging study. Females must be postmenopausal for at least 1 year, surgically sterile, or practicing birth control throughout the study and for 90 days after study completion. Female subjects tested negative in pregnancy test (serum test) at Week 24 in prior adalimumab study, if capable of pregnancy. Exclusion Criteria: A subject who experienced any of the following during prior study: Advanced or poorly controlled diabetes Joint surgery (joint evaluated in this study) A subject who has been prescribed excluded medications during prior study. History of following during prior study: Clinically significant drug or alcohol abuse Intravenous (iv) drug abuse Active infection with listeria or tuberculosis (TB) Lymphoma, leukemia And, any malignancy with the exception of successfully treated non-metastatic basal cell carcinoma of the skin. A subject who has been administered a live vaccine during prior study, or subject scheduled to complete the administration of a live vaccine during the study period
Sites / Locations
Arms of the Study
Arm 1
Experimental
Adalimumab 40 mg every other week (eow)